Voss Capital LP Sells 205,000 Shares of REGENXBIO Inc. $RGNX

Voss Capital LP reduced its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 41.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 295,000 shares of the biotechnology company’s stock after selling 205,000 shares during the quarter. Voss Capital LP’s holdings in REGENXBIO were worth $4,248,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,270 shares during the period. Profund Advisors LLC grew its position in REGENXBIO by 11.8% during the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock worth $139,000 after buying an additional 1,523 shares in the last quarter. Deutsche Bank AG grew its position in REGENXBIO by 0.8% during the fourth quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after buying an additional 1,527 shares in the last quarter. Intech Investment Management LLC grew its position in REGENXBIO by 12.2% during the fourth quarter. Intech Investment Management LLC now owns 21,367 shares of the biotechnology company’s stock worth $308,000 after buying an additional 2,327 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC grew its position in REGENXBIO by 24.0% during the fourth quarter. Focus Partners Advisor Solutions LLC now owns 12,676 shares of the biotechnology company’s stock worth $183,000 after buying an additional 2,455 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Steve Pakola sold 15,309 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $11.02, for a total value of $168,705.18. Following the completion of the transaction, the insider directly owned 232,617 shares in the company, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.22% of the company’s stock.

REGENXBIO Trading Up 6.1%

RGNX opened at $6.66 on Friday. The stock has a 50-day moving average price of $7.98 and a 200-day moving average price of $10.24. REGENXBIO Inc. has a 12-month low of $5.45 and a 12-month high of $16.19. The stock has a market capitalization of $344.32 million, a P/E ratio of -1.19 and a beta of 1.04.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The firm had revenue of $6.39 million during the quarter, compared to analysts’ expectations of $25.84 million. On average, equities research analysts predict that REGENXBIO Inc. will post -3.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RGNX. Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday. Bank of America reduced their target price on REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Morgan Stanley set a $16.00 target price on REGENXBIO in a research report on Friday, May 15th. Barclays reduced their target price on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Finally, HC Wainwright reduced their target price on REGENXBIO from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $23.55.

About REGENXBIO

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.